Forbesยท2025-05-21 20:35Core Viewpoint - Regeneron Pharmaceuticals is acquiring bankrupt genomics firm 23andMe for $256 million, aiming to utilize its extensive DNA database while committing to ethical standards in data privacy [1][2][4]. Company Overview - 23andMe, once valued at $6 billion, filed for bankruptcy in March 2025 due to declining consumer interest and a significant data breach that affected millions [3]. - The acquisition is seen as a strategic move for Regeneron to enhance its genomic-driven drug discovery processes using 23andMe's database of over 15 million DNA samples [2][3]. Data Privacy Commitments - Regeneron has pledged to adhere to 23andMe's existing privacy guidelines and relevant data protection regulations, ensuring that personal data will not be used for research without explicit consent [4][5]. - An independent overseer will evaluate the deal's impact on consumer privacy, with a report due to the bankruptcy court in June [4]. Regulatory and Ethical Concerns - The acquisition has raised concerns among privacy advocates regarding the handling of genetic information, especially in light of past data breaches [4][10]. - U.S. lawmakers are monitoring the situation, worried that genetic data could be sold to entities with different ethical standards [10]. Future Implications - The deal highlights broader questions about ownership and usage of personal genetic data, emphasizing the potential risks associated with sharing such information [13][14]. - As the acquisition moves toward finalization in the third quarter of 2025, the fundamental question remains whether the benefits of contributing to medical research outweigh the privacy risks [14][15].